Jenny Yu
Chemical and Life Sciences Industry Practice Leader, Risk Management
-
United Kingdom
Together they cover some of the key risks in an IPO and a De-SPAC transaction within the Life Sciences Industry, and how D&O insurance may help mitigate some of the risks. There are a number of financial benefits of an IPO, SPAC merger / De-SPAC, however, this does mean materially changing a company’s risk profile, by adding significant exposure to the personal assets of a company’s Directors and Officers.
This video offers practical advice on these types of risks, and how they can be mitigated from a D&O insurance perspective. Finally considering the 2022 outlook for the Life Sciences sector.
Chemical and Life Sciences Industry Practice Leader, Risk Management
United Kingdom
Public Offerings Lead, FINPRO, Private Equity and M&A, Marsh Specialty
United Kingdom